According to a recent Micro Market Monitor report, the American clinical chemistry analyzers market is expected to reach $1,496.4 million by 2019, growing a CAGR of 5.2%.
Clinical chemistry is a diagnostic method which tests blood, urine and other body fluids for chemical components such as blood glucose, electrolytes, enzymes, hormones, lipids (fats), other metabolic substances, and proteins. There are different types of tests to evaluate almost any kind of component.
Clinical chemistry is a key segment of the vitro diagnostics (IVD) market. The Americas is the largest market for clinical chemistry analyzers. The report identifies the main factors driving the growth of this market as
- Increasing healthcare expenditure
- Increasing aging population
- High prevalence of lifestyle diseases such as diabetes
- Rise in rental agreements
- Increasing medical insurances
The report categorizes the market on the basis of different types of analyzers, end-users, and technology. Clinical chemistry analyzers can be semi-automated or fully automated and end users include hospitals, diagnostic centers, and academic research institutes. The market is further segmented on the basis of major countries such as the U.S., Canada, Mexico, Chile, and Rest of Americas (RoA). The U.S., with a high aging population and the greatest number of people with diabetes, is the leading contributor to the clinical chemistry analyzers market in America.
Micro Market Monitor also predicts that the North American clinical chemistry market will reach $19,231.0 million by 2019, growing at a CAGR of 7.2%. The leading segment, point-of-care under IVD, is also expected to reach $8,919.0 million by 2019.
The key players in the market are F. Hoffmann La-Roche (Switzerland) Siemens AG (Germany), Abbott Laboratories (U.S.), Danaher Corporation (US), Ortho Clinical Diagnostics (US), and Thermo Fisher Scientific Inc., (U.S.).